Efficacy, Self Clinical Trial
— NANSAOfficial title:
Neuromodulation of the Autonomic Nervous System in Athletes (NANSA Trial)
NCT number | NCT06281795 |
Other study ID # | 1.24. |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2024 |
Est. completion date | January 31, 2026 |
There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels.
Status | Recruiting |
Enrollment | 125 |
Est. completion date | January 31, 2026 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 35 Years |
Eligibility | Inclusion Criteria: - Professional athletes over the age of 15 and under the age of 35; - Cyclic sports (swimming, modern pentathlon, athletics, triathlon); - Difficult coordination sports (dance sports, rhythmic gymnastics); - Sports category: no lower than candidate for master of sports; - Voluntary informed consent. Exclusion Criteria: - Atypical and unrelated to physical exertion changes on the ECG (T wave inversion, st-segment depression, pathological Q waves, signs of left atrial enlargement, signs of right ventricular hypertrophy, ventricular pre-excitation, complete right or left bundle branch block, prolonged or shortened Q-T interval, Brugada-like early repolarization); - Heart rhythm and conduction disorders (frequent ventricular and supraventricular extrasystoles, first-degree atrioventricular block (P-Q > 0.21 s, not shortened during hyperventilation or physical exertion), second or third degree); - Expressed sinus bradycardia with resting heart rate < 40 bpm; - Taking glucocorticosteroids in the last 1 month; - Taking any antiarrhythmic drugs, including beta-blockers. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION | Krasnodar |
Lead Sponsor | Collaborator |
---|---|
Bakulev Scientific Center of Cardiovascular Surgery | Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION, Foundation for the Support of Physical Culture and Sports BECOME A CHAMPION |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dynamics of maximum oxygen consumption (VO2max). | During a cardiorespiratory exercise test, the level of VO2max (ml/min/kg) is assessed. | The level of VO2max is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and fictitious stimulation groups. | |
Primary | The dynamics of the treadmill speed at the level of the anaerobic threshold of metabolism. | During the cardiorespiratory exercise test, the treadmill speed (km/h) is estimated at the level of the anaerobic metabolic threshold. | Treadmill speed is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups. | |
Secondary | Dynamics of the treadmill speed at the level of the aerobic metabolism threshold of metabolism. | During the cardiorespiratory exercise test, the treadmill speed (km/h) is estimated at the level of the aerobic metabolic threshold. | Treadmill speed is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups. | |
Secondary | The dynamics of the heart rate (HR) at the level of the anaerobic threshold of metabolism. | During the cardiorespiratory exercise test, the HR is estimated at the level of the anaerobic metabolic threshold. | HR is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups. | |
Secondary | The dynamics of the heart rate (HR) at the level of the aerobic threshold of metabolism. | During the cardiorespiratory exercise test, the HR is estimated at the level of the aerobic metabolic threshold. | HR is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups. | |
Secondary | The dynamics of RMSSD. | During the time analysis of heart rate variability, the RMSSD parameter is estimated. | This parameter is evaluated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the groups of active and fictitious stimulation. | |
Secondary | HF dynamics | During the spectral analysis of heart rate variability, the HF (high frequency) parameter is estimated. | This parameter is evaluated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the groups of active and fictitious stimulation. | |
Secondary | Dynamics of the LF/HF ratio. | The LF/HF ratio is estimated during the spectral analysis of heart rate variability. | This LF/HF ratio is evaluated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and fictitious stimulation groups. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04301206 -
Videos and Simple Text to Empower Parents to Handle Their Sick Children
|
N/A | |
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Recruiting |
NCT05803213 -
Learning Efficacy and Motivation of Medical Students in Clinical Training With Virtual Reality
|
N/A | |
Completed |
NCT06223412 -
Visual Based Program and Climate Change
|
N/A | |
Completed |
NCT05786638 -
Efficacy of Sublingual Versus Subcutaneous Allergen Immunotherapy in Patients With Bronchial Asthma
|
N/A | |
Active, not recruiting |
NCT04690725 -
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583006 -
Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B
|
||
Not yet recruiting |
NCT03733652 -
Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients
|
N/A | |
Recruiting |
NCT04998721 -
A Dyadic Approach to Perinatal Depression in Primary Care: Maternal Infant and Dyadic Care
|
Phase 2 | |
Recruiting |
NCT06288165 -
Lower Silesia Sinus Reducer Registry
|
||
Active, not recruiting |
NCT05842083 -
On-site Supportive Communication Training in Doctor-patient Communication
|
N/A | |
Recruiting |
NCT06451146 -
Lower Silesian Orbital Atherectomy Registry (LOAR)
|
||
Recruiting |
NCT05916898 -
The Lower Silesia Shockwave Registry
|
||
Recruiting |
NCT03524495 -
Well-being of Shelter Guests in Vancouver
|
N/A | |
Completed |
NCT04561466 -
Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT04341714 -
Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic
|
||
Recruiting |
NCT04541524 -
Vienna Preserflo Cohort Study
|
||
Recruiting |
NCT05825729 -
Diagnostic Efficacy Of 3 EUS-FNB Techniques
|
Phase 4 | |
Completed |
NCT03750877 -
Median and Paramedian Approach in Spinal Anesthesia
|
N/A | |
Completed |
NCT05141929 -
Effect of Web-Based Education on Gestational Diabetes Mellitus and Health Management Self Efficacy
|
N/A |